(Total Views: 351)
Posted On: 12/09/2019 1:35:54 PM
Post# of 145900
Quote:
Two of the world’s biggest pharmaceutical companies agreed to pay substantial premiums to acquire smaller cancer-drug makers, underlining the eagerness of the drug giants to add promising treatments to their oncology pipelines.
In separate deals announced Monday, Merck & Co. agreed to buy ArQule Inc., which is developing drugs known as kinase inhibitors, for $2.7 billion, while French drug giant Sanofi agreed to buy Synthorx Inc., a maker of therapies that harness the immune system to fight tumors, for $2.5 billion.
Both proposed transactions come with hefty price tags. In the ArQule deal, Merck will make a tender offer of $20 a share, more than double the smaller company’s closing price Friday. And in its deal for Synthorx, Sanofi agreed to pay nearly three times its target’s market value.
Why is it not possible for us to get such a deal when our drug is that magnificient wonder drug-like?
I just do not get it.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)